Skip to main content
Clinical Trials/NCT05538429
NCT05538429RecruitingNot Applicable

Comparison of Analgesic Effect and Postoperative Recovery of Serratus Anterior Plane Block Combined With Erector Spinae Plane Block and Thoracic Paravertebral Block After Thoracoscopic Surgery

Zhangyi1 site in 1 country92 target enrollmentStarted: June 1, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
92
Locations
1
Primary Endpoint
The dose of opioids used

Study Overview

Brief Summary

After thoracoscopic surgery, patients still face moderate to severe pain. How to effectively control pain and promote postoperative recovery of patients is a challenging problem. Thoracic paraspinal block is effective in controlling pain after thoracoscopic surgery, but it also carries the risk of difficulty in operation and puncture of the pleura. In recent years, erector spinal plane block and serratus anterior plane block have been used for postoperative analgesia after thoracoscopic surgery. The purpose of this study was to explore whether erector spinal plane combined with serratus anterior plane block can replace thoracic paravertebral block and provide a more complete analgesia after thoracoscopic surgery. Therefore, this study is of great clinical significance.

Detailed Description

In a double-blind randomized controlled study, investigators allocated 92 patients undergoing VATS to either SAPB Combined With ESPB or TPB, with both groups receiving otherwise standardized treatment, including multimodal analgesia. The primary outcome was 24-hr opioid consumption. Secondary outcomes included the number of survival analgesia at 1, 2, 4, 8, and 24 hours postoperatively ,VAS scores was assessed during resting and coughing statuses at 1, 2, 4, 8, and 24 hours postoperatively, pulmonary function indexes before and 1, 4, 24 hours after surgery , QOR-15 scores before and 24 hours after surgery, postoperative complications and recovery time nodes drainage tube removal time, discharge time.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • American ASA Grade I-III;
  • Age: 18 ~ 70 years old;
  • 3 BMI 19 ~ 28kg/m2;
  • Patients with elective thoracoscopic partial pneumonectomy under general anesthesia;
  • 5 Informed Consent has been signed.

Exclusion Criteria

  • Use opioid analgesics on a daily basis or have a history of opioid abuse;
  • History of ipsilateral thoracotomy;
  • Allergic to any of the drugs used in the study, or have a history of drug allergy;
  • Mental or nervous system diseases, motor or sensory deficits;
  • 5 there is coagulation dysfunction;
  • Cognitive dysfunction, unable to cooperate with research;
  • Severe renal, hepatic or cardiac dysfunction;
  • Chest wall and spine trauma, infection, deformity and other cases where nerve block cannot be performed;
  • Participated in other clinical trials within the 3 months prior to study inclusion;
  • Investigators consider other reasons unsuitable for clinical trial participants;
  • Patients refuse to participate.

Outcomes

Primary Outcomes

The dose of opioids used

Time Frame: 24 hours after surgery

dosage of analgesic pump

Secondary Outcomes

  • The dose of opioids used(1hour, 2hours, 4hours, 8hours and 48hours postoperatively after surgery)
  • pulmonary function indexes(Preoperative, postoperative 1hour, postoperative 4hours and postoperative 24hours)
  • Postoperative complications and recovery time nodes(follow up patients for an average of half a month)
  • The number of survival analgesia(1hour, 2hours, 4hours, 8hours, 24hours and 48hours after surgery)
  • VAS scores at resting and coughing state(1hour, 2hours, 4hours, 8hours, 24hours and 48hours after surgery)
  • QOR-15 scores(before and 24 hours after surgery)

Investigators

Sponsor
Zhangyi
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Zhangyi

Professor

Tongji Hospital

Study Sites (1)

Loading locations...

Similar Trials